Pharmacological treatment in adults with attention deficit hyperactivity disorder;Die medikamentöse behandlung der aufmerksamkeitsdefizit-/ hyperaktivitätsstörung im erwachsenenalter

Nervenarzt

Volumn 75, Issue 11, 2004, Pages 1074-1082

  Frolich J ^a   Lehmkuhl, G ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Adults; Antidepressants; Attention deficit hyperactivity disorder; Comorbidities; Psychostimulants

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; CARBAMAZEPINE; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; METHYLPHENIDATE; PEMOLINE; PROPRANOLOL DERIVATIVE; RITADEX; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ATTENTION DEFICIT DISORDER; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEART ARRHYTHMIA; HUMAN; LIVER TOXICITY; NEUROLOGIC DISEASE; REVIEW; SIDE EFFECT; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

ADULT; ANTIDEPRESSIVE AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CLINICAL TRIALS; COMORBIDITY; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS;

EID: 15244352711     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-004-1756-x     Document Type: Review

References (100)

1. Adler LA, Resnick S, Kunz M et al. (1995) Open-label trial of venlafaxine in adults with attention-deficit disorder. Psychopharmacol Bull 31:785-788
2. Barkley RA (1977) A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry 18:137-165
3. Barkley RA (1998) Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. Guilford Press, Weinheim
4. Barkley RA, DuPaul GJ, Mc Murray MB (1991) Attention-deficit disorder with and without hyperactivity: clinical response to three dose levels of methylphenidate. Pediatrics 87:519-531
5. Beck M, Krüger HP, Berglik W et al. (1997) Erhöhtes Unfallrisiko hyperkinetischer Kinder im Erwachsenenalter. MMW 34:376-378
6. Bemporad JR (2001) Aspects of psychotherapy with adults with attention deficit disorder. Ann NY Acad Sci 931:302-309
7. Berkovitch M, Pope E, Philips J et al. (1995) Pemoline - associated fulminant liver failure: testing the evidence for causation. Clin Pharmacol Ther 57:696-698
8. Biederman J, Baldessarini RJ, Wright V et al. (1989) A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry 28:777-784
9. Biederman J, Wilens T, Mick E et al. (1999) Pharmacotherapy of attention deficit hyperactivity disorder reduces for substance abuse disorder. Pediatrics 104:e20
10. Biedermann J, Wilens T, Mick E et al. (1995) Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry 152 (11):1652-1658
11. Biedermann J, Spencer T (2002) Methylphenidate in treatment of adults with attention-deficit/hyperactivity disorder. J Atten Disord 6 (Suppl 1):101-107
12. Botsic JQ, Biederman J, Spencer TJ et al. (2000) Pemoline treatment of adolescents with attention-deficit hyperactivity disorder: a short-term controlled trial. J Child Adolesc Psychopharmacol 10:205-216
13. Bradley C (1937) The behavior of children receiving benzedrine. Am J Psychiatry 94:577-585
14. Cantwell DP, Swanson J, Connor DH (1997) Case study: adverse response to clonidine. J Am Acad Child Adolesc Psychiatry 36:539-544
15. Castellanos FX, Giedd JN, Elia J et al. (1997) Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulants and dose. J Am Acad Child Adolesc Psychiatry 36:589-596
16. Celgene Corp. Celgene (1999) D-MPH (ATTENADE) shows longer duration of action in pivotal trials than most common ADHD drugs. Press release, Sept 9
17. Collier CP, Soldin SJ, Swanson JM et al. (1985) Pemoline pharmacokinetics and long-term therapy in children with attention-deficit disorder and hyperactivity. Clin Pharmacokinet 10:269-278
18. Conners CK, Erhardt D, Epstein et al. (1999) Self ratings of ADHD symptoms in adults. I: Factor structure and normative data. J Atten Disord 3:141-151
19. Cox DJ, Penberthy JK, Merkel RIK et al. (2002) Driving performance among adolescents with attention-deficit hyperactivity disorder: medication effects. Department of Psychiatric Medicine, Charlottesville poster. Presented at the 16th European College of Neuropsychopharmacology Congress, October 5-9, Barcelona, Spain
20. Diamond I, Tannock R, Schachar R (1999) Response to methylphenidate in children with ADHD and comorbid anxiety. J Am Acad Child Adolesc Psychiatry 38:402-409
21. Dresel S, Krause J, Krause K-H et al. (2000) Attention deficit hyperactivity disorder: binding of [99mTc] TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med 27:1518-1524
22. Dulcan M (1997) AACAP guidelines. Practice parameters for the assessment and treatment of children adolescents, and adults with attention deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 36 (Suppl 10S):85-121
23. DuPaul G, Barkley R, Mc Murray M (1994) Response of children with ADHD to methylphenidate: interaction with internalizing symptoms: J Am Acad Child Adolesc Psychiatry 33:894-903
24. DuPaul GJ, Barkley RA, Connor DF (1998) Stimulants. In: Barkley RA (ed) Attention-deficit hyperactivity disorder. Guilford Press, New York, pp 510-551
25. Erenberg G, Cruse RP, Rothner AD (1985) Gilles de la Tourette's syndrome: effects of stimulant drugs. Neurology 29:1346-1348
26. Ernst M, Liebenauer LL, Jons PH et al. (1996) Selegeline in adults with attention-deficit hyperactivity disorder: clinical efficacy and safety. Psychopharmacol Bull 32:327-334
27. Faraone SV, Doyle AE, Mick E et al. (2001) Metaanalysis of the association between the 7-repeat allele of the Dopamine D (4) receptor gene and attention-deficit hyperactivity disorder. Am J Psychiatry 158:1052-1057
28. Fegert J (2003) ADHS - Führerschein und Medikation. Nervenheilkunde 22:376-378
29. Findling RL, Schwartz MA, Flannery DJ et al. (1996) Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatry 57:184-189
30. Findling RL (1996) Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. J Child Adolesc Psychopharmacol 6:165-175
31. Fine S, Johnson C (1993) Drug and placebo side effects in methylphenidate-placebo trial for attention-deficit hyperactivity disorder. Child Psychiatry Hum Dev 24:25-30
32. Fisher M (1997) The persistence of ADHD into adulthood: it depends on whom you ask. ADHD Rep 5:8-10
33. Gadow KD, Werd H, Sprafkin J et al. (1995) Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry 52:444-455
34. Garland EJ (1998) Intranasal abuse of prescribed methylphenidate. J Am Acad Child Adolesc Psychiatry 37:573-574
35. Gualtieri CT, Hicks RE, Patrick K et al. (1984) Clinical correlates of methylphenidate blood levels. Drug Monit 6:379-392
36. Hedges D, Reimherr FW, Rogers A et al. (1995) An open trial of venlafaxine in adult patients with attention-deficit hyperactivity disorder. Psychopharmacol Bull 31:779-783
37. Heiligenstein E, Guenther G, Levy A et al. (1999) Psychological and academic functioning in college students with attention deficit hyperactivity disorder. J Am Coll Health 47:181-185
38. Heiligenstein JH, Spencer TJ, Faries DE et al. (2002)Tomoxetine, methylphenidate, placebo: comparison of treatment effects in children with ADHD. Presented at the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, October 24-29, New York
39. Horrigan JP, Barnhill LJ (2000) Low-dose amphetamine salts and adult attention-deficit/ hyperactivity disorder. J Clin Psychiatry 61:414-417
40. Iaboni F, Bouffard R, Minde K et al. (2000) The efficacy of methylphenidate in treating adults with attention-deficit hyperactivity disorder (abstract). Proc Am Acad Child Adolesc Psychiatry, Oct 2000, Philadelphia
41. Kinsbourne M, De Qiuros GB, Tocci Rufo D (2001) Adult ADHD. Controlled medication assessment. Ann NY Acad Sci 931:287-296
42. Krause K-H, Krause J (1999) Diagnostik und Therapie der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung im Erwachsenenalter. Dtsch Med Wochenschr 124:1309-1313
43. Lambert NM, Hartsough CS (1998) Prospective study of tobacco smoking and substance dependence among smoking and substance dependence among samples of ADHD and non-ADHD subjects. J Learn Disabil 31:533-544
44. Langer DH, Sweeney KP, Bartenbach DE et al. (1986) Evidence of lack of abuse or dependence following pemoline treatment: results of a retrospective survey. Drug Alcohol Depend 17:213-227
45. Leimkuhler ME (1994) Attention deficit disorder in adults and adolescents: cognitive behavioral and personality styles in the pschotherapists' guides to neuropsychiatry. In: Nadeau KG (ed) American Psychiatric Press, Washington, pp 175-216
46. Levy F (1993) Side effects of stimulant use. J Pediatr 29:250-254
47. Levy H, Hay DA, McStephen M et al. (1997) Attention deficit hyperactivity disorder: a category or a continuum? Genetic analysis of a large-scale twin study. J Am Acad Child Adolesc Psychiatry 36:737-744
48. Madras BK, Miller GM, Fishman AJ (2002) The dopamine transporter: relevance to attention deficit hyperactivity disorder (ADHD). Behav Brain Res 130:57-63
49. Mattes JA (1986) Propanolol for adults with temper outbursts and residual attention-deficit disorder. J Clin Psychopharmacol 6:299-302
50. Mattes JA, Boswell L, Oliver H (1994) Methylphenidate effects on symptoms of attention deficit disorder in adults. Arch Gen Psychiatry 41:1050-1063
51. MTA Cooperative group (1999) A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56:1073-1086
52. MTA Cooperative group (1999) Moderators and mediators of treatment response for children with ADHD: the MTA study. Arch Gen Psychiatry 56:1088-1096
53. Murphy KR, Barkley RA (1996) Prevalence of DSM IV symptoms in ADHD in adult licensed drivers: implications for clinical diagnosis. J Atten Disord 1:147-161
54. Nadeau KG (1995) A comprehensive guide to attention-deficit disorder in adults. Brunner/Mazel, New York
55. Nadeau KG (1995) Life management skills for the adults with ADD. In: Nadeau KG (ed) A comprehensive guide to attention deficit disorder in adults. Brunner/Mazel, New York, pp 191-217
56. Parran TV, Jasinski DR (1991) Intravenous methylphenidate abuse: prototype for prescription drug abuse. Arch Intern Med 151:781-783
57. Patrick KS, Markowitz JS (1997) Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder. Hum Psychopharmacol 12:527-546
58. Pelham WE, Greenslade KE, Vodde-Hamilton M et al. (1999) Relative efficacy of long-acting stimulants on children with ADHD: a comparison of standard methylphenidate, sustained-released methylphenidate, sustained-released dextroamphetamine, and pemoline. Pediatrics 86:226-237
59. Pelham WE, Aroffnoff HR, Midlam JK et al. (1999) A comparison of ritalin and adderall: efficacy and time course in children with Attention-deficit/ Hyperactivity disorder. 103:1-14
60. Pelham WE, Gnagy E, Burrows-MacLean et al. (2001) Once-a-day Concerta methylphenidate vs. three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107:e105
61. Pellock JM (1996) Pharmacological treatment of children with attention-deficit hyperactivity disorder syndrome: when to start and when to stop. Int Pediatrics 11:295-299
62. Physician's desk reference (1995) PDR. Medical Economics Data Production Company, Montvale
63. Pliszka SR (1987)Tricyclic antidepressants in the treatment of children with attention deficit disorder. J Am Acad Child Adolesc Psychiatry 26:127-132
64. Pliszka SR (1991) Antidepressants in the treatment of child and adolescent psychopathology. J Clin Child Psychol 20:313-320
65. Pliszka SR (1992) Comorbidity of attention-deficit hyperactivity disorder and overanxious disorder. J Am Acad Child Adolesc Psychiatry 31:197-203
66. Pliszka SR, Mc Cracken JT, Maas JW (1996) Cathecholamines in attention deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 35:264-272
67. Pliszka SR, Browner R, Olvera RL et al. (2000) A double-blind placebo-controlled trial of Adderall and methylphenidate in the treatment of attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 39:619-626
68. American Academy of Child and Adolescent Psychiatry (2002) Practice parameters for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41 (Suppl 2):26S-49S
69. Rapport MD, Carlson GA, Kelley KL et al. (1993) Methylphenidate and desipramine in hospitalized children: I. separate and combined effects on cognitive function. J Am Acad Child Adolesc Psychiatry 32:333-342
70. Reimherr FW, Hedges DW, Strong RE et al. (1995) An open trial of venlafaxine in adult patients with attention-deficit hyperactivity disorder (abstract). New Clinical Drug Evaluation Unit program. 35th Annual Meeting, Orlando
71. Shekim WO, Arsanow RF, Hess E et al. (1990) A clinical and demographic profile of a sample of adults with attention-deficit hyperactivity disorder, residual state. Compr Psychiatry 31:416-425
72. Singer HS, Brown H, Quaskey S et al. (1995) The treatment of attention-deficit hyperactivity disorder in Tourette syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics 95:74-81
73. Solanto MV (2002) Dopamine dysfunction in AD/HD. Integrating clinical and basic neuroscience research. Behav Brain Res 130:65-71
74. Spencer T, Wilens TE, Biederman J et al. (1995) A double-blind, cross-over comparison of methylphenidate and placebo in adults with childhood onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 52:434-443
75. Spencer T, Biederman J, Wilens T et al. (1996) Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 35:409-432
76. Spencer T, Biederman J, Wilens T et al. (1998) Effectiveness and tolerability of tomeoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155:693-695
77. Spencer T, Biederman J, Wilens T et al. (2001) Efficacy of mixed amphetamine in adults with attention deficit/ hyperactivity disorder. Arch Gen Psychiatry 58:775-782
78. Swanson JM, Lerner M, Williams L (1995) More frequent diagnosis of attention deficit-hyperactivity disorder. N Engl J Med 333:944
79. Swanson JM, Sergeant JA, Taylor E et al. (1998) Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet 351:429-433
80. Swanson JM, Wigal SB, Lerner MA (2000) Comparison of the efficacy and safety of OROS methylphenidatetid and placebo in children with ADHD. Pediatr Res 47:34A
81. Szatmari P, Offord DR, Boyle MH (1989) Ontario child health study: prevalence of attention-deficit disorder with hyperactivity. J Abnorm Child Psychol 30:219-230
82. Thapar A, Hervas A, McGuffin P (1995) Childhood hyperactivity scores are highly heritable and show sibling competition effects: twin study evidence. Behav Genet 25:537-544
83. Wall SC, Gu H, Rudnick G (1995) Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamines specifity for inhibition and efflux. Mol Psychiatry 47:544-550
84. Ward MF, Wender PH, Reimherr FW (1993) The Wender Utah Rating scale; an aid in the retrospective diagnosis of childhood attention-deficit hyperactivity disorder. Am J Psychiatry 150:885-890
85. Weiss G, Hechtman LT, Milroy T et al. (1985) Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Psychiatry 24:211-220
86. Wender PH, Reimherr FW (1990) Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry 147:1018-1020
87. Wender PH, Reimherr FW, Wood D et al. (1985) A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry 142:547-552
88. Wilens TE, Biederman J, Spencer TJ et al. (1995) Pharmacotherapy of adult attention-deficit hyperactivity disorder: a review. J Clin Psychopharmacol 15:270-279
89. Wilens TE, Biederman J, Prince J et al. (1996) Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 153:1147-1153
90. Wilens TE, Frazier J, Spencer TJ et al. (1996) A double-blind comparison of pemoline in adults with ADHD: preliminary results. Proc Am Acad Child Adolesc Psychiatry, Philadelphia (abstract)
91. Wilens TE, Biederman J, Spencer TJ (1998) Pharmacotherapy of attention-deficit hyperactivity disorder in adults. CNS Drugs 347-356
92. Wilens TE, Biederman J, Spencer TJ et al. (1999) Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 19:257-264
93. Wilens TE, Mc Dermott S (2000) Cognitive therapy for adults with attention-deficit/hyperactivity disorder. In: Brown TE (ed) Attention-deficit disorders an comorbidities in children, adolescents, and adults. American Psychiatric Press, Washington, pp 569-6075
94. Wilens TE, Farone SV, Biedermann J et al. (2003) Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111 (1):179-185
95. Wilens TE, Spencer TJ, Biederman J et al. (2001) A controlled trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 158:282-289
96. Wilens TE, Spencer TJ, Biedermann J (2002) A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J Atten Disord 5:189-202
97. Wolraich M, Greenhill LL, Pelham W et al. (2001) Randomized controlled trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics 108:883-892
98. Wolraich ML (2000) Evaluation of efficacy and safety of OROS methylphenidate HCL (MPH) extended release tablets, methylphenidate tid, and placebo in children with ADHD. Pediatr Res 47:36A
99. Wood DR, Reimherr FW, Wender PH (1983) The use of I-deprenyl in the treatment of attention-deficit disorder, residual type (ADD, RT). Psychopharmacol Bull 19:627-629
100. Zaczek R, Battiglia G, Contrera JF et al. (1989) Methylphenidate and pemoline do not cause depletion of rat brain monoamine markers similar to that observed with methamphetamine. Toxicol Appl Pharmacol 100:227-233